Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An update from Krystal Biotech ( (KRYS) ) is now available.
On July 24, 2025, Jeune Aesthetics, a subsidiary of Krystal Biotech, announced positive results from a Phase 1 study of KB304 for treating wrinkles of the décolleté. The study showed significant improvements in skin attributes such as wrinkles and elasticity, with KB304 outperforming placebo. The company plans to advance KB304 to Phase 2 development, aiming to fill a market gap for FDA-approved injectables in this area.
The most recent analyst rating on (KRYS) stock is a Buy with a $208.00 price target. To see the full list of analyst forecasts on Krystal Biotech stock, see the KRYS Stock Forecast page.
Spark’s Take on KRYS Stock
According to Spark, TipRanks’ AI Analyst, KRYS is a Outperform.
Krystal Biotech’s overall stock score is driven by strong financial performance and positive earnings call insights, highlighting significant revenue growth and strategic market expansions. Technical indicators and valuation reflect cautious optimism, while recent corporate events signal promising future developments.
To see Spark’s full report on KRYS stock, click here.
More about Krystal Biotech
Krystal Biotech, Inc. is a global biotechnology company focused on genetic medicines for diseases with high unmet needs, including dermatology and aesthetics. Jeune Aesthetics, Inc., a subsidiary, leverages a gene-delivery platform to address aging skin.
Average Trading Volume: 361,835
Technical Sentiment Signal: Hold
Current Market Cap: $4.43B
See more insights into KRYS stock on TipRanks’ Stock Analysis page.